Beximco Pharmaceuticals Limited (BXP.L)
GBp 36.5
(0.0%)
GBp 36.5
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 8.68 Billion BDT | N/A |
| 2022 | 9.37 Billion BDT | -4.35% |
| 2021 | 8.24 Billion BDT | 6.25% |
| 2020 | 7.38 Billion BDT | 27.69% |
| 2019 | 5.83 Billion BDT | 13.9% |
| 2018 | 5.12 Billion BDT | 27.53% |
| 2017 | 4.71 Billion BDT | 13.14% |
| 2016 | 3.52 Billion BDT | 13.21% |
| 2015 | 3.1 Billion BDT | 7.49% |
| 2014 | 2.9 Billion BDT | 3.8% |
| 2013 | 2.77 Billion BDT | 6.85% |
| 2012 | 2.59 Billion BDT | 9.0% |
| 2011 | 2.3 Billion BDT | 20.58% |
| 2010 | 1.94 Billion BDT | 90.29% |
| 2009 | 1.02 Billion BDT | 4.25% |
| 2008 | 979.92 Million BDT | 46.55% |
| 2007 | 673.2 Million BDT | -13.46% |
| 2006 | 783.27 Million BDT | 6.21% |
| 2005 | 727.46 Million BDT | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 Q3 | 2 Billion BDT | -5.57% |
| 2023 Q1 | 2.69 Billion BDT | 66.11% |
| 2023 Q2 | 2.12 Billion BDT | -21.34% |
| 2022 Q1 | 2.19 Billion BDT | 69.35% |
| 2022 FY | - BDT | -4.35% |
| 2022 Q4 | 1.62 Billion BDT | 4.97% |
| 2022 Q3 | 1.54 Billion BDT | -22.19% |
| 2022 Q2 | 1.98 Billion BDT | -9.28% |
| 2021 Q4 | 1.29 Billion BDT | -30.9% |
| 2021 Q3 | 1.87 Billion BDT | -23.38% |
| 2021 Q2 | 2.44 Billion BDT | 14.85% |
| 2021 FY | - BDT | 6.25% |
| 2021 Q1 | 2.12 Billion BDT | 30.77% |
| 2020 Q2 | 1.79 Billion BDT | 3.17% |
| 2020 Q3 | 2.12 Billion BDT | 18.32% |
| 2020 Q4 | 1.62 Billion BDT | -23.31% |
| 2020 Q1 | 1.73 Billion BDT | 23.18% |
| 2020 FY | - BDT | 27.69% |
| 2019 FY | - BDT | 13.9% |
| 2019 Q4 | 1.41 Billion BDT | -2.97% |
| 2019 Q3 | 1.45 Billion BDT | 6.7% |
| 2019 Q2 | 1.36 Billion BDT | -5.07% |
| 2019 Q1 | 1.43 Billion BDT | 8.82% |
| 2018 Q4 | 1.32 Billion BDT | 8.1% |
| 2018 FY | - BDT | 27.53% |
| 2018 Q2 | 1.21 Billion BDT | 1.22% |
| 2018 Q1 | 1.2 Billion BDT | 13.97% |
| 2018 Q3 | 1.22 Billion BDT | 0.4% |
| 2017 Q3 | 899.85 Million BDT | -9.56% |
| 2017 FY | - BDT | 13.14% |
| 2017 Q4 | 1.05 Billion BDT | 17.16% |
| 2017 Q2 | 994.97 Million BDT | 5.94% |
| 2017 Q1 | 939.17 Million BDT | 15.47% |
| 2016 Q2 | 917.38 Million BDT | 5.15% |
| 2016 Q1 | 872.46 Million BDT | -7.95% |
| 2016 Q4 | 813.31 Million BDT | -1.32% |
| 2016 FY | - BDT | 13.21% |
| 2016 Q3 | 824.23 Million BDT | -10.15% |
| 2015 Q4 | 947.79 Million BDT | 13.24% |
| 2015 Q1 | 755.23 Million BDT | -1.98% |
| 2015 FY | - BDT | 7.49% |
| 2015 Q2 | 786.2 Million BDT | 4.1% |
| 2015 Q3 | 836.97 Million BDT | 6.46% |
| 2014 Q1 | 768.62 Million BDT | 0.94% |
| 2014 Q4 | 770.51 Million BDT | 9.4% |
| 2014 FY | - BDT | 3.8% |
| 2014 Q2 | 702.01 Million BDT | -8.67% |
| 2014 Q3 | 704.33 Million BDT | 0.33% |
| 2013 Q2 | 739.92 Million BDT | 3.51% |
| 2013 FY | - BDT | 6.85% |
| 2013 Q4 | 761.44 Million BDT | 31.23% |
| 2013 Q1 | 714.85 Million BDT | -0.12% |
| 2013 Q3 | 580.23 Million BDT | -21.58% |
| 2012 Q4 | 715.73 Million BDT | 34.51% |
| 2012 Q2 | 892.47 Million BDT | 37.83% |
| 2012 Q1 | 647.5 Million BDT | 10.99% |
| 2012 FY | - BDT | 9.0% |
| 2012 Q3 | 532.1 Million BDT | -40.38% |
| 2011 Q3 | 594.05 Million BDT | -6.99% |
| 2011 Q4 | 583.39 Million BDT | -1.8% |
| 2011 Q2 | 638.67 Million BDT | -3.19% |
| 2011 FY | - BDT | 20.58% |
| 2011 Q1 | 659.69 Million BDT | 6.55% |
| 2010 Q3 | 450.05 Million BDT | 18.88% |
| 2010 Q1 | 608.03 Million BDT | 22.38% |
| 2010 FY | - BDT | 90.29% |
| 2010 Q4 | 619.11 Million BDT | 37.57% |
| 2010 Q2 | 378.58 Million BDT | -37.74% |
| 2009 Q4 | 496.84 Million BDT | 20.98% |
| 2009 Q3 | 410.67 Million BDT | 34.19% |
| 2009 FY | - BDT | 4.25% |
| 2009 Q1 | 343.41 Million BDT | 13.85% |
| 2009 Q2 | 306.03 Million BDT | -10.89% |
| 2008 Q4 | 301.64 Million BDT | 37.89% |
| 2008 FY | - BDT | 46.55% |
| 2008 Q3 | 218.75 Million BDT | 0.0% |
| 2007 FY | - BDT | -13.46% |
| 2006 FY | - BDT | 6.21% |
| 2005 FY | - BDT | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|